A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Not provided0 sites27 target enrollmentStarted: TBD

Conditions

Trial Snapshot

No summary available.

•A diagnosis of MASH documented in the participant's medical history, or a clinical suspicion of MASH based on non-invasive biomarkers and clinical risk factors, including having a history of 1 or more elements of metabolic syndrome as described in the protocol
•Screening percutaneous liver biopsy demonstrating a NAFLD Activity Score (NAS) >=4 and fibrosis stage F2 or F3 as described in the protocol
•Has a FibroScan Aspartate aminotransferase (FAST) score >0.35 either at Screening Visit 1 or within approximately 3 months of Screening Visit 1 as described in the protocol
•NOTE: Other Protocol-defined Inclusion Criteria Apply

•Known chronic liver disease other than Metabolic dysfunction-Associated steatotic Liver Disease (MASLD), as determined by the investigator as described in the protocol
•Prior or current suspected or known drug-induced liver injury within approximately 1 year prior to Screening Visit 1
•History of liver transplantation, current placement on a liver transplant list, or MELD score >12
•Known history of alcohol or other substance abuse within the last year or at any time during screening based on investigator's discretion and/or a score on the AUDIT questionnaire >=8
•Prior current, or planned future use of a Glucagon-Like Peptide-1 (GLP-1) receptor agonist-based therapy or any medication approved for the treatment of MASH unless used at a generally stable dose and regimen since at least 3 months prior to Screening Visit 1 or the qualifying historical liver biopsy and throughout the screening period with no change to the dose or regimen anticipated during the treatment period as described in the protocol
•NOTE: Other Protocol-defined Exclusion Criteria Apply

Sponsor

Not provided